Merck Stock News

CEO Rob Davis said Merck is on track to fulfill its commitment in the coming days of delivering 3.1 million courses of its Covid treatment pill to the U.S.

Merck (MRK) announced financial results for Q4 2021 ended December 31, 2021.Sales increased 24% Y/Y to $13.52B, ahead of analyst forecast of $13.14B

Wall Street will navigate a series of key S&P 500 earnings Thursday as investors look to forward projections from a host of companies amid concerns of rising inflation, Federal Reserve rate hikes and slowing consumer growth.

Merck & Co Inc''s (NYSE: MRK ) Q4 sales reached $13.52 billion , +24% Y/Y, beating the consensus of $13.16 billion. Excluding the foreign exchange impact, revenues were up 23%. Pharmaceutical sales increased 23% to $12 billion, reflecting sales of molnupiravir and growth in oncology, vaccines, and hospital acute care products. COVID-19 treatment drug Molnupiravir sales were $952 million, primarily consisting of sales Full story available on Benzinga.com

Merck''s Covid-19 antiviral pill, molnupiravir, had sales of $952 million in the quarter.

Merck''s Covid-19 antiviral pill, molnupiravir, had sales of $952 million in the quarter.

Merck&Co Earnings, Revenue Beat in Q4

Merck press release (MRK): Q4 Non-GAAP EPS of $1.80 beats by $0.28.Revenue of $13.52B (+23.5% Y/Y) beats by $380M.2022 Financial OutlookAnticipates Full-Year 2022 Worldwide Sales to

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors

US regulators are considering the first COVID-19 vaccine for children under the age of 5, the only age group not yet eligible for the shots, after Pfizer Inc and BioNTech SE began the regulatory approval process on Tuesday, February 1. A decision is expected as soon as this month. The companies said they began submitting data for an emergency use authorization even though they did not meet a key target in their clinical trial of 2- to 4- year olds. They are submitting the data at the request of the US Food and Drug Administration in order to address an urgent public health need in the age group, they said. The arrival of a vaccine for younger children could help harried parents who have had to contend with quarantines and closures of pre-schools and daycare centers. Having a safe and effective vaccine available for children in this age group is a priority, acting FDA Commissioner Janet Woodcock said. She said the agency asked for the application because of the recent Omicron surge. The FDA said an outside committee of expert advisers would meet on February 15 to discuss the authorization.

Sellas Life Sciences <> completed enrollment in a phase 1/2 trial of its lead asset galinpepimut-S ((GPS)) in combination with Mercks <> Keytruda (pembrolizumab) in second

Two Dow stocks and the country''s largest independent oil producer are reporting quarterly results before markets open Thursday.

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.